MENLO PARK, Calif., February 10, 2026--(BUSINESS WIRE)--OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced positive ...

MENLO PARK, Calif., January 16, 2026--(BUSINESS WIRE)--OrsoBio, Inc. ("OrsoBio" or "the Company"), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic ...

Mutations in LXRα lead to liver cholesterol buildup, hepatitis, and fibrosis in individuals on a Western diet, highlighting the receptor's role in maintaining liver health. Study: Damaging mutations ...

A metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma (GBM) has been discovered, report researchers who have shown how it can potentially be exploited for therapy. A ...

The liver X receptor (LXR) is a nuclear hormone receptor that is one of the most important regulators of cholesterol homeostasis and plays a key role in triglyceride (TG) regulation. Researchers from ...

Researchers at University of California (UC) San Diego School of Medicine, Ludwig Institute for Cancer Research and The Scripps Research Institute, with colleagues in Los Angeles and Japan, report ...

Lipid deposits (green) in brain immune cells (red) from mice with Alzheimer’s-like disease all but disappear (right) after the mice are treated with an experimental drug. Researchers at Washington ...

When we eat, our bodies convert extra calories, especially from carbs, sugar, fats, and alcohol, into molecules called “triglycerides”. Triglycerides are a form of fat or “lipid”, which the body ...

OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced positive topline results from a Phase 2a proof-of-concept study ...